Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Biocodex Microbiota Foundation Awards Grants to Two Innovative Researchers in the Microbiome Field

Biocodex North America
Posted on: 21 Mar 18

North American Drs. Singh and Fernandez will use the grants from the Biocodex Research Foundation to field new research that examines dietary interactions with the gut microbiome in gastrointestinal disorders

REDWOOD CITY, Calif., March 20, 2018 /PRNewswire/ -- The Biocodex Microbiota Foundation (BMF), an organization founded by Biocodex North America and dedicated to inspiring scientific projects that explore the structure of microbiota, has announced two winners – Dr. Rashim Singh from the United States and Dr. Alberto Caminero Fernandez from Canada – in its first-ever call for proposals to study dietary interactions with microbiota. Each of the winners will receive grants from the foundation to fund their microbiota research projects.

Dr. Singh, with the University of Houston's pharmacological and pharmaceutical sciences department, was awarded the grant for her project, "Flavonoids and microbiome interactions via triple recycling and their roles in food-borne carcinogen-induced colorectal cancer." Dr. Singh's study will investigate the role of gut microbiome and its constitution in the increased risk of colorectal cancer (CRC), and the potential for flavonoids to counteract that risk. "The results of this study would be critical towards understanding the flavonoid-microbiome interaction and its role in the prevention of CRC caused by the dietary carcinogens," Singh writes in her research proposal.

Dr. Fernandez, with Ontario Farncombe Family Digestive Health Research Institute, McMaster University, was awarded the grant for his project, "The role of commensal microbiota on dietary tryptophan metabolism: Implications for inflammatory bowel disease." In the research project, Dr. Fernandez will isolate and characterize microbes involved in tryptophan metabolism from patients with inflammatory bowel disease (IBD), and from healthy controls. "Our long-term goal is to develop combinations of bacteria that act on tryptophan dietary sources and produce AhR agonists to prevent and treat IBD," he writes in his proposal.

Biocodex, a global pharmaceutical company and maker of the probiotic Florastor®, has been a leading researcher and provider in the microbiota field for the last 60 years. As the company continues to evolve, more emphasis has been placed on increasing awareness and placing reputable data at the fingertips of both consumers and healthcare professionals. To push this initiative forward, Biocodex launched in tandem the Biocodex Microbiota Foundation and the Biocodex Microbiota Institute (BMI) in June of 2017. Together, these two entities will help advance research and our understanding of the human microbiota and gut flora – work that's sorely needed in the United States and around the world. In fact, healthcare professionals reported to the BMI that only 10 percent of the American population discuss flora and gut health with their doctors and pharmacists.

The Biocodex Microbiota Foundation's annual call for projects is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies. The grants favor young investigators and may be applied to a new or an existing ongoing study.

The applications were reviewed and the winners chosen by BMF's scientific boards, comprised of Dr. Ruth Ann Luna from Texas Children's Hospital and Baylor College of Medicine, Dr. Emeran Mayer from University of California Los Angeles (UCLA), Dr. Daniel Merenstein from Georgetown University, Dr. Leo Dieleman from University of Alberta and Dr. Elena Verdu from McMaster University.

The Biocodex Microbiota Foundation will be continuing the grant initiative each year, and the call for projects will be opening up again in Spring 2018. For more information, visit http://www.biocodexmicrobiotafoundation.com/foundation.

About Biocodex North America
Biocodex North America is a Silicon Valley-based pharmaceutical company dedicated to providing its customers with meaningful healthcare solutions with an emphasis on gastroenterology and oncology supportive care. Florastor® Daily Probiotic Supplements remain the flagship products, available at all major retailers nationwide. Biocodex North America is a subsidiary of Biocodex, a family-owned multinational pharmaceutical, research, development, manufacturing, and commercial enterprise operating in more than 100 countries. Visit http://www.biocodexusa.com/ or http://www.biocodex.ca/en/ for more information.

About Biocodex Microbiota Foundation
The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies. Research is supported through grants given to projects that investigate the implication of microbiota in human health. BMF supports both foundational and applied research, and projects are selected annually by a committee of independent, international scientists.

The BMF's primary activity remains the awarding of annual grants to innovative scientific research projects that explore the structure and impact of microbiota. The BMF also runs and helps establish programs to improve our understanding of microbiota and disseminates this knowledge as widely as possible. Finally, the BMF can establish public projects involving microbiota which aim to help improve human health.

The Biocodex Microbiota Foundation (BMF) is a non-profit, general interest organization.

Contact:
SSPR
Kayli Berlin
kberlin@sspr.com
(650) 240-6926

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 21/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.